石四药(02005.HK)大输液销售目标保持为16亿
石四药(02005.HK)执行董事王宪军於记者会指,公司大部份药物都列入国家名册中,而今年新增一只阿比多尔胶囊被纳入国家2019版医保目录,相信整体正面。
他指,保持大输液16亿的销售目标,上半年已售7.8亿,相信下半年销售会较上半年多,有信心全年可达标。他指现时有关市场已由400多家下降至10多间,而首5间已占市场份额80-90%。
至於出口方面,他指上半年销量增13%,与销售增速一致,长远希望保持在占销售比例10%。
他表示,公司会继续坚持「仿创结合」的新产品开发,以注射剂为基础,下半年有望取得6项注射剂和口服制剂生产批件,并会提升安瓿产品的产能,而河北广祥制药一期原料药项目已竣工及投入试生产,预期月内进行GMP认证现场检查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.